Last reviewed · How we verify
NCT05512221: (GBAT+)
Transdiagnostic Group Therapy (GBAT) for Autistic Adults With Personalized Therapeutics
NA trial testing GBAT+I, GBAT+E - Phase I in GBAT+Individual in 33 participants. Completed in 1 July 2024.
1 July 2024
Quick facts
| Lead sponsor | Rutgers, The State University of New Jersey |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 33 |
| Start date | 23 September 2022 |
| Primary completion | 1 July 2024 |
| Estimated completion | 1 July 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- GBAT+I, GBAT+E - Phase I
- Watchful Waiting and Groups - Phase 2
- GBAT+IE
Conditions studied
- GBAT+Individual — all drugs for GBAT+Individual →
- GBAT+Engagement Booster — all drugs for GBAT+Engagement Booster →
- GBAT+Both — all drugs for GBAT+Both →
Sponsor
Rutgers, The State University of New Jersey
Who can join
Adults 18 to 40, any sex, with GBAT+Individual or GBAT+Engagement Booster. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to build upon an earlier study that evaluated the use of a 10-week transdiagnostic Group Behavioral Activation Therapy (GBAT), a telehealth delivered intervention, as a cost effective and accessible way to treat symptoms of anxiety and depression in autistic adults. The current study will pilot and compare relative feasibility, acceptability, and preliminary efficacy of three adapted GBAT groups and a Watchful Waiting (WW) group. The three groups include GBAT+Individual (GBAT+I; individual sessions to supplement the 10 group sessions), GBAT+Engagement Booster (GBAT+E; supplemental materials), and GBAT+Both (GBAT+IE individual sessions and supplemental materials).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05512221
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Rutgers, The State University of New Jersey trials
Trials by the same sponsor.
- NCT07243886 — Mobile-based Obstetric Monitoring for Pregnancies Complicated by Hypertension and/or Diabetes (MOM-HD) · NA · not yet recruiting
- NCT06955130 — Lactate and Glycerol Contribution to Gluconeogenesis · NA · not yet recruiting
- NCT06822010 — SeqUential GeMcitabine and MITomycin Treatment for Favorable High-Risk Upper Urinary Tract Urothelial Carcinoma · Phase 2 · not yet recruiting
- NCT07525011 — Comparative Study of Denture Fabrication Techniques · NA · not yet recruiting
- NCT06834204 — Advancing Care Coordination Between Cancer and Primary Care Teams for Complex Cancer Survivors · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05512221 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rutgers, The State University of New Jersey
- Last refreshed: 29 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05512221.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing